Israeli generic drug giant Teva to buy Cephalon

May 02, 2011

Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.

Teva, headquartered in , said the acquisition would help to expand and diversify it products, including into new areas such as .

The friendly takeover comes after Cephalon last month rejected a hostile $5.7 billion bid from Canadian firm Valeant.

Teva offered $81.50 in cash for all of Cephalon's shares outstanding, representing a 39 percent premium on Cephalon's share value at the end of March, before Valeant launched its .

The Teva offer values Cephalon at $6.8 billion, including debt.

Both companies' board of directors unanimously agreed to the deal.

Teva said the acquisition was not conditioned on obtaining financing and was expected to be completed in the third quarter of 2011.

"The transaction reinforces Teva's long-term strategy of building out its branded and specialty pharmaceuticals business through diversification and expansion of the company's product portfolio and pipeline," the Israeli group said.

The combined company will become "a leader in specialty pharma" and will have a "sizable" branded portfolio that represents about $7 billion in sales, it said.

Founded in 1987, Cephalon had $2.8 billion in revenue in 2010. The company employs 4,000 people worldwide and specializes in cancer and pain treatments.

Explore further: Xtoro approved for swimmer's ear

add to favorites email to friend print save as pdf

Related Stories

Cephalon biotech rejects $5.7 billion Valeant bid

Apr 06, 2011

US biotech group Cephalon has rejected a hostile, $5.7 billion acquisition bid from its Canadian rival Valeant, which counter-attacked by seeking to replace the firm's board of directors.

Roche to take over Genentech for $47 billion

Mar 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

EMC counters NetApp bid for Data Domain

Jun 01, 2009

US computer storage giant EMC Corp. offered 1.8 billion dollars on Monday for Data Domain in a bid to counter a rival offer for the data storage company from NetApp.

EMC raises offer for Data Domain

Jul 06, 2009

Computer storage giant EMC raised its offer to purchase data storage firm Data Domain on Monday in a bid to top a rival offer for the company by data management firm NetApp.

Genzyme board rejects Sanofi bid

Aug 30, 2010

The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday. ...

Recommended for you

Xtoro approved for swimmer's ear

20 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

21 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.